# Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer

> **NCT06353906** · PHASE2 · RECRUITING · sponsor: **The Netherlands Cancer Institute** · enrollment: 27 (estimated)

## Conditions studied

- Urologic Neoplasms
- Urogenital Neoplasms
- Male Urogenital Diseases
- Penile Cancer
- Penile Squamous Cell Carcinoma
- Locally Advanced Penile Carcinoma

## Interventions

- **DRUG:** Carboplatin/Paclitaxel
- **DRUG:** Pembrolizumab
- **PROCEDURE:** Partial or total penectomy with inguinal and/or pelvic lymph node dissection

## Key facts

- **NCT ID:** NCT06353906
- **Lead sponsor:** The Netherlands Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-08-13
- **Primary completion:** 2026-10-14
- **Final completion:** 2028-01-14
- **Target enrollment:** 27 (ESTIMATED)
- **Last updated:** 2025-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06353906

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06353906, "Carboplatin/Paclitaxel + Pembrolizumab for Locoregionally Advanced Penile Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06353906. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*